Resource Type

Journal Article 25

Year

2023 2

2022 1

2021 4

2020 3

2019 1

2018 1

2017 2

2016 3

2015 2

2014 1

2012 1

2011 1

2009 1

open ︾

Keywords

monoclonal antibody 5

SARS-CoV-2 4

neutralizing antibody 3

COVID-19 2

Monoclonal antibody 2

hapten 2

-acetylglucosamine 1

Nsp9 1

γ3 1

Allergic disease 1

Anti-IgE 1

Antibody–drug conjugate 1

Antigen 1

B cell response 1

B-cell acute lymphoblastic leukemia 1

B7-H3 1

BALB/C mice 1

Bactrian camel 1

Bispecific antibody 1

CD19 1

open ︾

Search scope:

排序: Display mode:

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

Frontiers of Medicine 2021, Volume 15, Issue 4,   Pages 644-648 doi: 10.1007/s11684-021-0847-4

Abstract: The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirusCurrently, the receptor-binding domain (RBD) of the spike (S) protein is the main target of neutralizingantibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-convertingA single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibilityThus, a cocktail therapy combining two or more antibodies that recognize different regions of the viral

Keywords: neutralizing antibody     antibody cocktail     SARS-CoV-2     COVID-19     therapeutic strategy    

Passive antibody therapy in emerging infectious diseases

Frontiers of Medicine doi: 10.1007/s11684-023-1021-y

Abstract: Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonalantibodies (mAbs) applied in passive immunotherapy have yielded positive outcomes and played a crucial

Keywords: SARS-CoV-2     COVID-19     convalescent plasma     hyperimmunoglobulin     neutralizing monoclonal antibodies    

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

Qian Wang, Linqi Zhang

Frontiers of Medicine 2020, Volume 14, Issue 1,   Pages 30-42 doi: 10.1007/s11684-019-0721-9

Abstract: Recent discoveries in broadly neutralizing monoclonal antibodies (bNAbs) has led to the development of

Keywords: HIV-1     broadly neutralizing antibodies     Env conformational states     vaccine design     SOSIP    

Human monoclonal antibodies as candidate therapeutics against emerging viruses

Yujia Jin, Cheng Lei, Dan Hu, Dimiter S. Dimitrov, Tianlei Ying

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 462-470 doi: 10.1007/s11684-017-0596-6

Abstract: Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer

Keywords: human monoclonal antibodies     emerging infectious diseases     SARS-CoV     MERS-CoV     Ebola virus    

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 746-751 doi: 10.1007/s11684-020-0822-5

Abstract: Here we examined, using ELISA, the IgG antibodies in serum specimens collected from 17 COVID-19 patientsNotably, 14 samples available at 6−7 months post-infection all showed significant neutralizing activities

Keywords: SARS-CoV-2     neutralizing antibodies     T-cell response    

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in

Yulu Wang, Dan Hu, Yanling Wu, Tianlei Ying

Frontiers of Medicine 2020, Volume 14, Issue 2,   Pages 149-159 doi: 10.1007/s11684-020-0764-y

Abstract: Moreover, designing a universal influenza vaccine that is sufficiently immunogenic to induce universal antibodieshidden in the hemagglutinin (HA) trimeric interface have been discovered recently, and a number of antibodiestargeting these epitopes have been found to be capable of neutralizing a broad range of influenza isolatesIn this review, we focused on the antibodies targeting these newly discovered epitopes in the HA domainof the influenza virus to promote the development of universal anti-influenza antibodies or vaccines

Keywords: influenza virus     neutralizing antibody     hemagglutinin     globular head region     trimeric interface    

Antibodies Targeting a Conserved Surface Polysaccharide Are Protective Against a Wide Range of Microbial

Xi Lu,Guoqing Li,Jing Pang,Xinyi Yang,Colette Cywes-Bentley,Xuefu You,Gerald B. Pier,

Engineering doi: 10.1016/j.eng.2023.09.012

Abstract: PNAG-based vaccines and PNAG-targeting antibodies have shown great efficacy in preclinical research.Furthermore, clinical tests for both vaccines and antibodies have been carried out in humans and economically

Keywords: Poly-     N     -acetylglucosamine     Conjugate vaccine     Monoclonal antibody    

Preparation of hapten-specific monoclonal antibody for cadmium and its ELISA application to aqueous samples

Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA

Frontiers of Environmental Science & Engineering 2011, Volume 5, Issue 3,   Pages 409-416 doi: 10.1007/s11783-011-0349-8

Abstract: High-affinity and specific monoclonal antibodies against cadmium-ethylene diamine tetraacetic acid (EDTAThe monoclonal antibody with high level of binding affinity for Cd-IEDTA-BSA and high specificity for

Keywords: cadmium     hapten     monoclonal antibody     enzyme-linked immunosorbent assay (ELISA)    

Synthesis of haptens and production of antibodies to bisphenol A

Xiya ZHANG, Xiaoyun DONG, Sijun ZHAO, Yuebin KE, Kai WEN, Suxia ZHANG, Zhanhui WANG, Jianzhong SHEN

Frontiers of Agricultural Science and Engineering 2017, Volume 4, Issue 3,   Pages 366-372 doi: 10.15302/J-FASE-2017132

Abstract: bisphenol A (BPA), including two new haptens, were used to produce highly sensitive and specific polyclonal antibodiesHighly sensitive polyclonal antibodies were obtained and characterized using indirect competitive enzyme-linked

Keywords: bisphenol A     cross-reactivity     hapten     indirect competitive ELISA     polyclonal antibody    

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 83-93 doi: 10.1007/s11684-019-0682-z

Abstract: Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC havethat EGFR and S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal

Keywords: S492R EGFR ectodomain mutation     colorectal cancer     mAb CH12     immunnotherapy    

Characterization of polyclonal antibodies against nonstructural protein 9 from the porcine reproductive

Mengmeng ZHAO,Juanjuan QIAN,Jiexiong XIE,Tiantian CUI,Songling FENG,Guoqiang WANG,Ruining WANG,Guihong ZHANG

Frontiers of Agricultural Science and Engineering 2016, Volume 3, Issue 2,   Pages 153-160 doi: 10.15302/J-FASE-2016097

Abstract: Antibodies against 9 will be of great importance for the diagnosis and treatment of the causal agentA study was undertaken to generate polyclonal antibodies against the immunodominant 9.

Keywords: PRRSV     Nsp9     expression     antibody     neutralize    

From SARS to MERS: evidence and speculation

Hainv Gao,Hangping Yao,Shigui Yang,Lanjuan Li

Frontiers of Medicine 2016, Volume 10, Issue 4,   Pages 377-382 doi: 10.1007/s11684-016-0466-7

Abstract:

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic pathogen. In 2012, the infectious outbreak caused by MERS-CoV in Saudi Arabia has spread to more than 1600 patients in 26 countries, resulting in over 600 deaths. Without a travel history, few clinical and radiological features can reliably differentiate MERS from SARS. But in real world, comparing with SARS, MERS presents more vaguely defined epidemiology, more severe symptoms, and higher case fatality rate. In this review, we summarize the recent findings in the field of MERS-CoV, especially its molecular virology, interspecies mechanisms, clinical features, antiviral therapies, and the further investigation into this disease. As a newly emerging virus, many questions are not fully answered, including the exact mode of transmission chain, geographical distribution, and animal origins. Furthermore, a new protocol needs to be launched to rapidly evaluate the effects of unproven antiviral drugs and vaccine to fasten the clinical application of new drugs.

Keywords: middle east respiratory syndrome     animal origin     cross-species transmission     monoclonal antibody    

The biopharmaceutical industry in China: history and future perspectives

Kai Gao, Junzhi Wang

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 101-111 doi: 10.1007/s11684-012-0191-9

Abstract:

Biopharmaceuticals reflect the rapid progress achieved in modern biomedical research. This area has also become one of the main criteria for assessing the development level of biotechnology for a particular country. Although it has been only three decades since the first biopharmaceutical, recombinant human insulin, was licensed by the US Food and Drug Administration, the biopharmaceutical industry has become the fastest growing, most dynamic and technology-intensive sector in the biomedical field. Since the licensing of recombinant human interferon α1b in 1989, the biopharmaceutical industry in China has gone through initial developments and gradually entered a period of rapid growth. This paper provides an overview of the status and development trends of biopharmaceuticals in China, and compares them with those observed in developed countries.

Keywords: biopharmaceuticals     antibodies     market trends     diseases     China     national regulatory agency    

Emerging immunological strategies: recent advances and future directions

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 805-828 doi: 10.1007/s11684-021-0886-x

Abstract: that promote anti-tumor immunity have recently been developed, such as small molecules, bispecific antibodiesBispecific antibodies, which bind two different antigens or one antigen with two different epitopes,

Keywords: cancer immunotherapy     bispecific antibodies     small molecules     chimeric antigen receptor T therapy     cancer    

Anti-β glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two

Wenjing Zhang,Fei Gao,Donghe Lu,Na Sun,Xiaoxue Yin,Meili Jin,Yanhong Liu

Frontiers of Medicine 2016, Volume 10, Issue 1,   Pages 76-84 doi: 10.1007/s11684-015-0426-7

Abstract:

Anti-β2 glycoprotein I (anti-β2GP I ) antibodies are importantHowever, the mechanism by which anti-β2GP I antibodies are involved in the pathogenesisIn this report, we investigated the role of anti-β2GP I antibodies in complexes with

Keywords: anti-β2GP I /β2GP I complex     platelet     GP I bα     apoER2'     thrombosis    

Title Author Date Type Operation

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

Journal Article

Passive antibody therapy in emerging infectious diseases

Journal Article

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

Qian Wang, Linqi Zhang

Journal Article

Human monoclonal antibodies as candidate therapeutics against emerging viruses

Yujia Jin, Cheng Lei, Dan Hu, Dimiter S. Dimitrov, Tianlei Ying

Journal Article

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen

Journal Article

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in

Yulu Wang, Dan Hu, Yanling Wu, Tianlei Ying

Journal Article

Antibodies Targeting a Conserved Surface Polysaccharide Are Protective Against a Wide Range of Microbial

Xi Lu,Guoqing Li,Jing Pang,Xinyi Yang,Colette Cywes-Bentley,Xuefu You,Gerald B. Pier,

Journal Article

Preparation of hapten-specific monoclonal antibody for cadmium and its ELISA application to aqueous samples

Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA

Journal Article

Synthesis of haptens and production of antibodies to bisphenol A

Xiya ZHANG, Xiaoyun DONG, Sijun ZHAO, Yuebin KE, Kai WEN, Suxia ZHANG, Zhanhui WANG, Jianzhong SHEN

Journal Article

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Journal Article

Characterization of polyclonal antibodies against nonstructural protein 9 from the porcine reproductive

Mengmeng ZHAO,Juanjuan QIAN,Jiexiong XIE,Tiantian CUI,Songling FENG,Guoqiang WANG,Ruining WANG,Guihong ZHANG

Journal Article

From SARS to MERS: evidence and speculation

Hainv Gao,Hangping Yao,Shigui Yang,Lanjuan Li

Journal Article

The biopharmaceutical industry in China: history and future perspectives

Kai Gao, Junzhi Wang

Journal Article

Emerging immunological strategies: recent advances and future directions

Journal Article

Anti-β glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two

Wenjing Zhang,Fei Gao,Donghe Lu,Na Sun,Xiaoxue Yin,Meili Jin,Yanhong Liu

Journal Article